一种血型抗原三糖B类似物蛋白偶联物及应用
By conjugating blood group antigen trisaccharide B analogues with hemocyanin or bovine serum albumin, the resulting protein conjugates can replace red blood cell reagents, solving the specificity and stability problems of artificially synthesized blood group antigens in existing technologies, and achieving efficient and low-cost blood group antibody detection.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- TIANJIN DEXIANG BIOTECHNOLOGY CO LTD
- Filing Date
- 2022-12-05
- Publication Date
- 2026-07-17
AI Technical Summary
In existing technologies, artificially synthesized blood group antigens have problems with specificity, affinity and stability, and cannot be effectively used for reverse identification. In addition, the storage and transportation requirements of red blood cell reagents are high, which increases the detection cost.
A blood group antigen trisaccharide B analog protein conjugate is provided, which forms a blood group antigen trisaccharide B analog protein conjugate by conjugating with hemocyanin or bovine serum albumin. This conjugate is used to replace red blood cell reagents in reverse chromatographic assays, especially in immunochromatographic assays, to stably fix and capture blood group antibodies.
It achieves highly specific and accurate blood type antibody detection, reduces testing costs, and is suitable for rapid blood type screening, POCT testing, and blood type self-testing for ordinary people. The color development effect is easy to identify, avoiding the cumbersome process of extracting and preparing natural blood type antigens.
Smart Images
Figure CN117269515B_ABST